Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Compass Therapeutics reported positive topline results from the COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer, meeting the primary ORR endpoint and key secondary PFS endpoint. Median progression-free survival was 4.7 months for the combination versus 2.6 months for paclitaxel alone, representing a 56% reduction in the risk of disease progression with a hazard ratio of 0.44.
Key figures
- Drug Name
- tovecimig
- Phase Of Trial
- Phase 2/3
- Pfs months
- 4.7
- Orr percent
- 17.1
- P value pfs
- <0.0001
- Hazard ratio
- 0.44
- Pfs control months
- 2.6
- Orr control percent
- 5.3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.